跳至主要内容
临床试验/NCT01593527
NCT01593527撤回3 期

A Randomized Double-blind Active-controlled Trial of Canakinumab Versus Triamcinolone Acetonide on Reducing the Proportion of Patients With Any New Gouty Arthritis Flare(s) in Patients With Chronic Kidney Disease

Novartis Pharmaceuticals0 个研究点开始时间: 2012年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
撤回
主要终点
Proportion of patients experiencing new gouty arthritis flares during 12-week follow-up from dosing

研究概览

简要总结

The purpose of this study is to confirm the efficacy and safety results obtained in a chronic kidney disease (CKD) subgroup of patients participating in Phase III studies in a larger, independent patient population with difficult to treat gouty arthritis and moderate to severe CKD (stage 3 - 4).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Arm 1

Experimental

Canakinumab 150 mg s.c.

干预措施: ACZ885 (Drug)

Arm 2

Experimental

Triamcinelone acetonide 40 mg i.m.

干预措施: Triamcinelone acetonide (Drug)

结局指标

主要结局

Proportion of patients experiencing new gouty arthritis flares during 12-week follow-up from dosing

时间窗: 12 Weeks

次要结局

  • Score on Visual Analog Scale at 72 hours to measure gouty arthritis pain intensity and resolution(12 weeks)
  • Number of patients needing rescue medication use during acute gouty arthritis flare(s)(12 Weeks)
  • Measurement of efficacy using inflammatory markers(12 Weeks)
  • Time to 50% reduction of baseline pain intensity in the most affected joint(12 weeks)
  • The time to the first new gout flare(12 Weeks)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验